Glucagon-like peptide-1 receptor agonists (GLP-1RAs) constitute a drug class primarily designed for the treatment of patients with T2DM, representing today’s cornerstone treatment approach for this disease. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.